Malaria Clinical Trial
Official title:
Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults
NCT number | NCT03503058 |
Other study ID # | IDSPZV1 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | May 7, 2022 |
Est. completion date | December 2024 |
The study is a double-blind, randomized, placebo-controlled, Phase 2 clinical trial that will assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring malaria in healthy Indonesian soldiers deployed to eastern Indonesia.
Status | Recruiting |
Enrollment | 372 |
Est. completion date | December 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - A male aged 18-55 years at the time of screening. - Assigned to the battalion of study and programmed to accompany it to eastern Indonesia for the duration of the deployment. - Freely provides written informed consent to participate in the study. - Agrees to adhere to Indonesian military medical guidance regarding screening and treatment of malaria. - Physical examination and laboratory results without clinically significant findings that would jeopardize the safety of the participant or the integrity of the study, and a body mass index (BMI) =35 kg/m^2. Exclusion Criteria: - Previous vaccination with an investigational malaria vaccine. - Use of an investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days before the first study vaccination, or planned use up to 30 days after last vaccination. - Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within six months before the first vaccination. This includes any dose level of oral steroids, but not inhaled steroids or topical steroids. - Administration or planned administration of 1 live or 3 or more other type vaccines in the period beginning 28 days before the first study vaccination and ending 28 days after the last vaccination. - Confirmed or suspected immunosuppressive or immunodeficient condition. - Confirmed or suspected autoimmune disease. - History of allergic reactions or anaphylaxis to CQ or other 4-aminoquinolone derivatives. - History of serious allergic reactions to a drug (anaphylaxis, or requiring hospitalization). - History of allergy to phosphate buffered saline or human serum albumin. - Use or planned use of any drug with anti-malarial activity during the course of the study except for antimalarial medication administered by study clinicians. - History of splenectomy. - Laboratory evidence of liver disease (the final decision will be made by the PI and clinical officers, but in general a volunteer will be excluded if any of the screening liver function tests (ALT, bilirubin, gamma GTP) are > double the upper limit of normal measured twice without an explanation for the abnormal values). - Laboratory evidence of renal disease (serum creatinine > 1.5 mg/dL. measured twice). - Laboratory evidence of hematologic disease (platelet count or hemoglobin <80% of the lower limit of normal for Indonesia measured twice). - Abnormal screening ECG showing prolonged QTc interval (>450 msec) or any signs of arrythmia/irregularity, ischemia, cardiac enlargement considered considered indicative of acute or chronic cardiovascular disease. - Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition, severe malnutrition, or any other clinical findings that may increase the risk of participating in the study as determined by the principal investigator or her designee. - Administration of immunoglobulin and/or any blood products within the three months preceding the first study vaccination or planned administration during the study period. - Simultaneous participation in any other interventional clinical trial. - Other conditions that in the opinion of the principal investigator or her designee would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol or might compromise the integrity of the data. - Any evidence of active malaria, whether symptomatic or asymptomatic, confirmed by RDT, microscopy or PCR before first injection of PfSPZ Vaccine or PfSPZ-CVac, unless treated by the clinical team. - History of non-febrile seizures or atypical febrile seizures. - Under treatment for tuberculosis. - Laboratory evidence of active infection with hepatitis B, or hepatitis C. - Subjects with > 10% 5-year cardiovascular risk (fatal and non-fatal) based on the Gaziano scoring system; subjects in the 18-34 year old age group will be assessed as though they are in the 35-44 age group. - History of psychiatric disorders (such as personality disorders, anxiety disorders, or schizophrenia) or behavioral tendencies (including active alcohol or drug abuse) discovered during the screening process that in the opinion of the investigator would make compliance with the protocol difficult. |
Country | Name | City | State |
---|---|---|---|
Indonesia | Department of Internal Medicine, Universitas Indonesia | Jakarta | |
Indonesia | Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology | Jakarta |
Lead Sponsor | Collaborator |
---|---|
Sanaria Inc. | Congressionally Directed Medical Research Programs, Eijkman Oxford Clinical Research Unit, Indonesia, Indonesia University |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of adverse events occurring after investigational product (IP) administration | a. The proportion of participants experiencing of solicited AEs occurring within 7 days (PfSPZ Vaccine) or 14 days (PfSPZ-CVac) of each administration of investigational product (IP). b) The proportion of participants experiencing serious adverse events (SAEs) deemed related to IP during active participation in the trial. c) The proportion of participants experiencing unsolicited AEs occurring within 14 days of each administration of IP deemed related to vaccination or placebo administration. |
a. 7 days (PfSPZ Vaccine) or 12 (first two doses) or 14 (third dose) days (PfSPZ-CVac) of each administration. b. From day of immunization until end of study (24 months). c. 14 days of each administration | |
Primary | The number of confirmed first infections with Pf | The number of confirmed first clinical malaria cases caused by Pf among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. | 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. | |
Secondary | The number of confirmed first infections* caused by Pf | The number of confirmed first infections* caused by Pf among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. * thick blood smears from asymptomatic individuals will be read retrospectively, so there is no interference in ascertaining the number of clinical cases, which is the primary VE endpoint. |
10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia | |
Secondary | The number of confirmed first clinical malaria cases caused by Pv | The number of confirmed first clinical malaria cases caused by Pv among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. | 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. | |
Secondary | The number of confirmed first infections with Pv in eastern Indonesia | The number of confirmed first infections* caused by Pv among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. * thick blood smears from asymptomatic individuals will be read retrospectively, so there is no interference in ascertaining the number of clinical cases, which is the primary VE endpoint. |
10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. | |
Secondary | The number of confirmed relapsing infections from Pv | The number of confirmed relapsing infections from latent liver stages of Pv identified post-exposure in a malaria-free area. | 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia. | |
Secondary | Humoral immune responses | The humoral immune responses* induced by vaccination compared to those induced by placebo administration comparing vaccinees to controls; (b) the association between the immune responses and protection (no parasitemia or clinical malaria occurring during surveillance). *(i) Levels of antibodies against Pf circumsporozoite protein (CSP) by ELISA 2 weeks after the third dose of vaccine; (ii) Optional: Levels of antibodies against PvCSP by ELISA 2 weeks after the third dose of vaccine; (iii) Optional: Levels of antibodies against other Pf and Pv proteins, PfSPZ, PvSPZ and Pf and Pv asexual erythrocytic stages (AES) 2 weeks after the third dose; (iv) Optional: inhibition of sporozoite invasion assay, |
14 days after the third dose of vaccine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02536222 -
Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts
|
Phase 4 |